Loading
Archives of Medical Case Reports
ISSN: 2691-7971
Imatinib Induced Hypopigmentation and Neutropenia in a Patient with Gastric Gastrointestinal Stromal Tumor
Imatinib is a selective inhibitor of the bcr-abl tyrosine kinase making it a potential treatment of chronic myelogenous leukemia (CML), as well as a selective inhibitor of KIT protein tyrosine kinase, and PDGF receptor, and is the treatment of choice in patients with gastrointestinal stromal tumors (GISTs)
Arch Med Case Rep, 2022, Volume 4, Issue 1, p1-5 | DOI: 10.33696/casereports.4.015Cortical Visual Impairment (CVI): An Atypical Manifestation of Osmotic Demyelination Syndrome in a Child
Osmotic Demyelination Syndrome (ODS) is a unique process of selective demyelination and destruction of oligodendrocytes and astrocytes in specific areas of the brain that usually occurs a few days after an osmotic stress [1]. ODS has been described most frequently in association with a rapid correction of hyponatremia, though it may occur with other electrolyte or metabolic abnormalities.
Arch Med Case Rep, 2021, Volume 3, Issue 1, p12-16 | DOI: 10.33696/casereports.3.014How to Prevent Rehospitalization in Patients with COVID-19
Since December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused by 2019 Novel Coronavirus (2019-nCoV) has resulted in 89,000 cases of Corona Virus Disease 2019 (COVID-19), formerly known as Novel Coronavirus Pneumonia (NCP) in China, including 2,450 deaths.
Arch Med Case Rep, 2021, Volume 3, Issue 1, p17-28 | DOI: 10.33696/casereports.3.013Primary Temporal Bone Meningioma Presenting as Chronic Mastoiditis and Sigmoid Sinus Thrombosis: Report of a Case with Literature Analysis
Meningiomas are common, primary brain tumors, accounting for up to 30% of intracranial neoplasms; they are usually slow-growing and benign [1]. Primary extra cranial meningiomas are rare, and approximately 2% of meningiomas are located extra cranially [2]. Furthermore, primary extra cranial meningiomas of the ear and temporal bone are exceedingly rare .
Arch Med Case Rep, 2021, Volume 3, Issue 1, p4-11 | DOI: 10.33696/casereports.3.011Avulsion of the Common Extensor Tendon and Radial Collateral Ligament Tear
A 59-year-old left hand dominant female was evaluated by a physical therapist. The patient had an 8-year history of chronic intermittent left elbow pain with a recent exacerbation occurring after moving furniture. Aggravating factors included holding a coffee cup, picking up trash bags, and lifting heavy dishes. Symptoms were eased by ice and Meloxicam as prescribed by her primary care provider.
Arch Med Case Rep, 2021, Volume 3, Issue 1, p1-3 | DOI: 10.33696/casereports.3.010Safety and Efficacy of s-MOX Regimen in Patients with Colorectal Cancer Who Developed Cardiotoxicity Following Fluoropyrimidine Administration: A Case Series
5-fluorouracil (5-FU), an antimetabolite in the fluoropyrimidine class, is the third most commonly used chemotherapeutic agent worldwide for the treatment of solid malignancies [1]. Despite advances in novel cancer therapies, commonly used in combination with fluoropyrimidines, 5-FU remains one of the most effective and safe chemotherapy agents to manage colorectal cancer (CRC).
Arch Med Case Rep, 2020, Volume 2, Issue 1, p23-29 | DOI: 10.33696/casereports.2.008The Global Rise of Chronic Diseases: Why Broaden the Paradigm to Include Tick-borne Illness and Environmental Toxin Exposure?
The incidence of chronic diseases is rapidly increasing worldwide. It has been calculated that, in 2001, chronic diseases contributed to approximately 46% of the global burden of disease and 60% of the total reported deaths with that number expected to increase to 57% by 2020, when chronic diseases will account for almost 75% of all deaths worldwide.
Arch Med Case Rep, 2019, Volume 1, Issue 1, p7-13 | DOI: 10.33696/casereports.1.003Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.